Introduction: The Enigma of Early-Onset Cryptogenic Stroke
Ischemic stroke in young adults—those aged 18 to 49—presents a significant clinical challenge. Unlike older populations where atherosclerosis and atrial fibrillation are the predominant drivers, nearly half of all strokes in younger patients are classified as cryptogenic, meaning they remain of undetermined origin despite extensive diagnostic evaluation. Recent research has increasingly pointed toward transient triggers that may tip the homeostatic balance toward thrombosis. Among these, infections have emerged as a primary suspect, potentially acting through complex thromboinflammatory pathways. The SECRETO study (Stroke in Young Fabry Patients, Early-onset Cryptogenic Stroke Study) provides new, multicenter evidence characterizing the association between preceding infections, coagulation biomarkers, and the risk of early-onset cryptogenic ischemic stroke (CIS).
Highlights of the SECRETO Findings
– Infections occurring within the week prior to a stroke are associated with a 2.64-fold increase in the odds of cryptogenic ischemic stroke.
– Elevated von Willebrand Factor (VWF) activity and Factor VIII (FVIII) levels are strongly linked to stroke risk, particularly in the presence of recent infection or fever.
– The association between infection and stroke is most pronounced in the immediate short-term window (one week), suggesting a transient, acute trigger mechanism.
– Cases showed significantly higher VWF activity compared to controls, especially when an infection was present.
Study Design and Methodology
The SECRETO study is a robust multicenter case-control study conducted across 19 European centers between 2013 and 2022. The study focused on first-ever patients with cryptogenic ischemic stroke aged 18 to 49 years. These cases were meticulously matched with age- and sex-matched controls.
To assess the impact of infections, researchers used a standardized questionnaire to evaluate self-reported preceding infections within a three-month window. Blood samples were collected at baseline (acute phase) and at a three-month follow-up to establish a baseline for coagulation biomarkers. The primary outcome was the association between these infections and the occurrence of CIS, analyzed using conditional logistic regression adjusted for traditional vascular risk factors. Secondary outcomes focused on specific biomarkers, including VWF, FVIII, fibrinogen, antithrombin III, and protein C.
Key Findings: Quantifying the Infection-Stroke Link
The analysis of 537 matched pairs yielded compelling data. After multivariable adjustment for demographic and vascular risk factors, infections occurring within the preceding week were associated with a 2.64-fold higher odds of CIS (95% CI, 1.34-5.20). This risk was notably higher than the risk associated with infections occurring further back in time, reinforcing the theory that the inflammatory response to an acute infection acts as a short-term trigger.
The Role of Coagulation Biomarkers
One of the most significant aspects of the SECRETO study is its focus on the biochemical mediators of this risk. The study found that VWF activity was substantially higher in stroke cases (122 IU/mL) compared to controls (100 IU/mL; P<0.001). When examining cases alone, those with a recent infection had markedly higher VWF levels (157 IU/mL) compared to cases without an infection (121 IU/mL).
Interestingly, this elevation in VWF was not observed in controls who had infections but did not suffer a stroke. This suggests a potential "double hit" or increased sensitivity to inflammatory triggers in individuals who go on to experience a stroke. Stratified analyses further showed that for every standard deviation increase in VWF and Factor VIII, the odds of stroke increased significantly, specifically among those with recent infections or fever.
Expert Commentary: Mechanistic Insights
The findings from the SECRETO study underscore a critical intersection between immunology and hematology—often referred to as thromboinflammation. Infections can trigger endothelial activation, lead to the release of ultra-large VWF multimers from Weibel-Palade bodies, and suppress natural anticoagulant pathways like protein C. In young patients who may not have significant atherosclerotic burden, this transient hypercoagulable state may be sufficient to cause a cryptogenic event.
The fact that VWF and Factor VIII levels were only significantly associated with stroke in the context of infection in this study suggests that these biomarkers are not just markers of chronic risk, but active participants in the acute triggering of a stroke. The lack of VWF elevation in infected controls suggests that stroke patients may have an underlying predisposition—perhaps genetic or related to endothelial health—that causes an exaggerated prothrombotic response to common infections.
Clinical Significance and Future Directions
For clinicians, these results emphasize the importance of taking a detailed infectious history in young patients presenting with stroke. While the study does not yet dictate a change in acute management, it opens the door for future research into preventive measures. Could short-term anti-inflammatory or enhanced antithrombotic therapy during an acute infection reduce stroke risk in high-risk young individuals?
Furthermore, the study highlights the potential utility of VWF and FVIII as biomarkers to identify patients at higher risk during inflammatory periods. Future research must elucidate why certain individuals exhibit this heightened sensitivity to inflammatory triggers and whether specific types of infections (viral vs. bacterial) carry different risk profiles.
Conclusions
This multicenter case-control study provides high-quality evidence that recent infections are a potent, transient trigger for cryptogenic ischemic stroke in young adults. By identifying VWF and Factor VIII as key mediators, the SECRETO study moves the field closer to understanding the thromboinflammatory mechanisms of early-onset stroke. Continued investigation into these pathways is essential to develop targeted prevention strategies and reduce the burden of stroke in the young population.
Funding and Clinical Trial Information
The SECRETO study was supported by various national research councils and health foundations across the participating European countries.
ClinicalTrials.gov Identifier: NCT01934725.
References
1. Hulsen BM, Spiegelenberg JP, Martinez-Majander N, et al. Preceding Infections and Coagulation Biomarkers in Early-Onset Cryptogenic Ischemic Stroke. Stroke. 2026;57(3):[In Press]. PMID: 41841261.
2. Putaala J. Ischemic stroke in the young. Continuing Medical Education. Neurology. 2020;26(2):505-514.
3. Grau AJ, et al. Recent infection and risk of stroke: a case-control study. Stroke. 2010;41(1):85-90.
4. Smeeth L, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. New England Journal of Medicine. 2004;351:2611-2618.
